Abstract:Abstract Background In patients with ST-elevation myocardial infarction (STEMI), a pharmacoinvasive (PI) strategy is the recommended reperfusion method if primary percutaneous coronary intervention (pPCI) cannot be performed within 120 minutes from diagnosis. Long-term prognosis for STEMI patients with long transfer distances to pPCI is sparsely documented. Purpose To compare short- and long-term survival, and cardiovascular (CV) death in STEMI patients treated with PI or pPCI strategy. Methods Consecutive STEMI patients admitted to our cardiac invasive centre were registered prospectively during 2005–2011 in a local quality registry. Follow-up data throughout 2013 were provided by the Norwegian Cause of death registry. Effects of treatment strategy were determined using a propensity score weighted analysis, adjusting for treatment-outcome confounding. Outcomes were 30-day mortality, overall survival and CV death during follow-up. Results Of 4762 STEMI patients, 543 (11.4%) were treated with thrombolysis before admission for rescue- or early coronary angiography (PI strategy), and 4044 (84.9%) were admitted for a pPCI strategy (3,7% excluded due to unspecified treatment strategy). Median age was 60 and 63 years in the PI and pPCI groups (19.5% and 24.1% women, respectively). Median time to reperfusion was 110 minutes (25–75th percentile: 75–163; symptom-to-thrombolysis) versus 230 minutes (149–435; symptom-to-balloon). Crude 30-day mortality was 3.9% and 6.6% in the PI- and pPCI groups. Median follow-up was 4.5 years (max 8.3 years). The overall 8-year survival was 84.6% (95% CI 79.4–88.4) in the PI group and 72.6% (95% CI 70.1–74.9) in the pPCI group (crude hazard ratio [HR] 0.56 (95% CI 0.43–0.72, p<0.0001). After propensity score weighting (based on age, gender, smoking, previous hypertension, stroke, diabetes, myocardial infarction, angina pectoris and peripheral artery disease, kidney function and pre-hospital resuscitation), patients had estimated 25% lower risk of long-term mortality with a PI strategy (weighted HR 0.75; 95% CI 0.53–1.07, p=0.113, Figure 1A). Cumulative incidence rate of CV death was 12.8 (PI strategy) and 27.8 (pPCI strategy) pr 1000 person-years (crude incidence rate ratio 0.46; 95% CI 0.32–0.68, p<0.0001), and was significantly lower in the PI group after weighting on the propensity score (p=0.048, Figure 1B). Conclusions There was a non-significant 25% lower risk of mortality up to 8 years with a PI versus pPCI strategy in STEMI patients with long transfer distances to PCI, after adjustment for treatment-outcome confounding. Importantly, long-term incidence of CV death was significantly lower in the PI group. These findings from real life practice support the use of a PI strategy in STEMI patients without contraindications to thrombolysis, when pPCI within 120 minutes from diagnosis is not possible. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Funded by grant form the Scientific Board of the Southeastern Norway Regional Health Authority, Hamar, Norway.

Effectiveness of PCI for Delayed STEMI Patients: Insights From Moroccan Cardiology Intensive Care Units.

The role of late reperfusion in ST-segment elevation myocardial infarction: a real-world retrospective cohort study

Pharmaco-invasive Therapy: A Continued Role for Fibrinolysis in the Primary PCI era

A comprehensive guide on the optimal timing of PCI in the setting of acute coronary syndrome: An updated meta-analysis

Treatment delay and reperfusion management of acute ST-segment elevation myocardial infarction: analysis of the China STEMI Care Project Phase 1

In-hospital Outcomes of Delayed Stenting in Hemodynamically Stable Patients with ST-segment Elevation Myocardial Infarction: the CCC (care for Cardiovascular Disease in China) Project.

Invasive reperfusion after 12 hours of the symptom onset remains beneficial in patients with ST-segment elevation myocardial infarction: Evidence from a meta-analysis of published data.

Implementing a comprehensive STEMI protocol to improve care metrics and outcomes in patients with in-hospital STEMI: an observational cohort study

Clinical assessment for the long-term benefits of delayed percutaneous transluminal coronary intervention in patients with acute myocardial infarction

Patients with ST-segment elevation of myocardial infarction miss out on early reperfusion: when to undergo delayed revascularization.

Emergency Percutaneous Coronary Intervention in Post-Cardiac Arrest Patients Without ST-Segment Elevation Pattern: Insights From the PROCAT II Registry

Electrocardiogram Score for the Selection of Reperfusion Strategy in Early Latecomers with ST-segment Elevation Myocardial Infarction

Impact of Different Clinical Pathways on Outcomes of Patients with Acute St-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: the Rapid-Ami Study

[Percutaneous Coronary Intervention in Acute Coronary Syndrome: Single Center Experience from 4670 Patients].

Influence of percutaneous coronary intervention timing on the prognosis of patients with acute ST segment elevation myocardial infarction

Effect of primary pci in asymptomatic stemi patients presenting 12 to 48 hours of symptom onset, on myocardial viability assessed by spect tc 99m sestamibi scan epitome99

Treatment Windows and Clinical Outcomes in Late-Presenting Patients with ST-Segment Elevation Myocardial Infarction

Late percutaneous coronary intervention prevents left ventricular remodeling and improves clinical outcomes in patients with ST-elevation myocardial infarction.

Delayed PCI is Not Beneficial for STEMI Patients with Impaired Renal Function: a Retrospective Cohort Study

Analysis of Hospital Outcomes of Early and Delayed PCI in Non-St Segment Elevation ACS

Long-term survival after a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction and long distances to primary percutaneous coronary intervention – a prospective cohort study